**Reviewer comments form**

|  |  |
| --- | --- |
| **Document:**  | **Guideline Premature Ovarian Insufficiency** |
| **Deadline for comments** | **27 May 2024** |

**Contact information of the reviewer**

|  |  |
| --- | --- |
| NAME  |  |
| COUNTRY |  |
| I AM PARTICIPATING |  | AS AN INDIVIDUAL |
|  | ON BEHALF OF A (INTER)NATIONAL ORGANIZATION, NAMELY \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | ON BEHALF OF A COMPANY, NAMELY \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| We will acknowledge the input of whomever submits comments by including a list of contributors in the stakeholder review report. |

**Statement of confidentiality**

I will not disclose any confidential and/or proprietary information, materials or data related to Guideline Development Group’s work to any third party, but keep this information strictly confidential.

I will keep any confidential and/or proprietary information, materials or data in my possession in a safe and secure place to protect against inadvertent disclosure.

I will not use any confidential information and/or proprietary information, materials or data for any purpose other than participating in an ESHRE guideline development procedure.

|  |  |
| --- | --- |
| SIGNATURE (OR TYPED NAME) |  |
| DATE |  |

**Comments to the document**

***General comments***

|  |  |
| --- | --- |
| **Topic** | **Comment** |
|  |  |
|  |  |

*(Add more table rows if you need to)*

***Specific comments to PART A: introduction to POI[[1]](#endnote-1)***

|  |  |  |
| --- | --- | --- |
| **Page**  | **Line/figure/****recommendation** | **Comment** |
|  |  |  |
|  |  |  |
|  |  |  |

***Specific comments to PART B: Diagnosis of POIi***

|  |  |  |
| --- | --- | --- |
| **Page**  | **Line/figure/****recommendation** | **Comment** |
|  |  |  |
|  |  |  |
|  |  |  |

***Specific comments to PART C: SEQUELAE OF POIi***

|  |  |  |
| --- | --- | --- |
| **Page**  | **Line/figure/****recommendation** | **Comment** |
|  |  |  |
|  |  |  |
|  |  |  |

*Please send completed forms (as word-document or pdf) to guidelines@eshre.eu before 27 May 2024. Handwritten or scanned forms will not be accepted.*

*All comments will be revised by the guideline group and assessed. If the comment is accepted by the group, it will result in a modification of the guideline. If not, the guideline group will formulate a reply. The details of the review procedure, the comments, modifications and replies, and the names of experts contributing to the review will be summarized in the stakeholder review report which will be available on the ESHRE website as an annex to the guideline.*

1. *Add more table rows if you need to* [↑](#endnote-ref-1)